Sign in

You're signed outSign in or to get full access.

Fawwad Qureshi

Chief Financial Officer at TRUPANIONTRUPANION
Executive

About Fawwad Qureshi

Chief Financial Officer of Trupanion since September 25, 2023; age 51; MBA (Boston University) and BA (St. Olaf). Prior roles include SVP Finance & CFO of Brands at Expedia (P&L responsibility for ~$9B portfolio), CFO for Nike Global Technology, and senior finance roles at Intel . Company performance during 2024: total revenue up 16% to $1,286M; subscription revenue up 20% to $856.5M; free cash flow $38.6M; net loss improved to $(9.6)M; operating cash flow $48.3M . Trupanion’s cumulative TSR (initial $100 investment) was $131.12 in 2024 vs $83.00 in 2023, reflecting improved market performance . In 2025, Qureshi led a lower-cost, three-year $120M credit facility with PNC Bank to enhance flexibility and support growth .

Past Roles

OrganizationRoleYearsStrategic Impact
Expedia GroupSVP Finance & CFO of BrandsApr 2022 – Jun 2023Full P&L and commercial responsibility across ~$9B brand portfolio (Expedia, Vrbo, Hotels.com, Orbitz, Travelocity)
NikeCFO, Global TechnologyOct 2019 – Apr 2022Managed omni-channel technology investment portfolio and digital product development
IntelSenior finance rolesNov 2000 – Sep 2019Progressive leadership across finance functions in a global enterprise

External Roles

  • None disclosed (no public company board seats or external directorships reported for Qureshi) .

Fixed Compensation

Component20242023
Base Salary ($)$400,000 (effective May 1, 2024; previously $300,000) $300,000 (pro-rated salary paid $81,250 post-hire)
All Other Compensation ($)$23,529 (relocation $20,704 and tax gross-up $2,825) $28,940 (travel reimbursement $17,457; tax gross-up $11,483)
Perquisites/BenefitsCompany-wide benefits; short‑term personal security provided to certain NEOs in 2025; Qureshi received tax gross-ups on travel expenses in 2023–2024

Performance Compensation

Short‑Term Incentive Structure and Outcomes (2024)

PeriodTarget Bonus (% of Salary)StructureMetrics/WeightingActual Payout (% of Target)Actual Payout ($)Form
Jan–Apr (Legacy)40% Monthly goals; paid after year-end for CFOCorporate 50%, Individual 50% 82% $74,173 Cash
May–Jun (Legacy)75% Monthly goals; paid after year-end for CFOCorporate 50%, Individual 50% Included above Included above Cash
Jul–Dec (MIP)75% 100% corporate metrics (AOI, LVP, IRR)AOI/LVP/IRR (no individual goals) 106% $158,640 Cash

MIP Metric Attainment (2H 2024)

MetricTargeting ApproachActual AttainmentNotes
Lifetime Value per Pet (LVP)Company-defined per-pet lifetime economics 200% of target Strong value creation per pet
Internal Rate of Return (IRR)Discount rate on pet lifetime cash flows 92% of target Discipline in PAC and retention
Adjusted Operating Income (AOI)Non-GAAP operating performance 65% of target Margin restoration in progress

Annual Long‑Term Incentive Awards (RSUs)

GrantGrant DateSharesGrant Date Fair Value ($)Vesting
Annual performance RSUs (2024 perf)Feb 202541,980 $2,044,006 Quarterly over 2 years (company standard)
Prorated 2023 performance RSUsFeb 27, 20247,304 $199,180 1/8th quarterly
Spot RSU (performance)Feb 27, 20245,000 $136,350 1/4 at ~1-year, then 1/16 quarterly
New‑hire RSUs (offer letter)Nov 2023 (granted Nov 13, 2023)60,000 Included in 2023 stock awards 25% at 1‑year, then monthly

Summary Compensation (Pay Mix)

YearSalary ($)Bonus ($)Stock Awards ($)Non‑Equity Incentive ($)All Other ($)Total ($)
2024$366,667 $154,024 $199,180 $232,813 $23,529 $976,212
2023$81,250 $1,362,000 $25,935 $28,940 $1,498,125

Equity Ownership & Alignment

  • Beneficial ownership as of April 16, 2025: 10,222 shares issuable within 60 days (vested RSUs scheduled to settle); less than 1% of shares outstanding .
  • Outstanding unvested RSUs at 12/31/2024: 45,000 (new-hire 11/13/2023), 5,000 (2/27/2024), 4,565 (2/27/2024), total 54,565 units .
  • Ownership guidelines: other executive officers must hold 3x base salary within 5 years; vested RSUs and in-the-money options count; hedging prohibited; pledging discouraged and requires pre-approval .
  • Section 16(a) compliance: one late Form 4 filed by Qureshi in Nov 2024 related to RSU vesting .
  • No pledging or hedging by Qureshi disclosed; company policy prohibits hedging and limits pledging .

Employment Terms

  • At‑will employment; start date September 25, 2023 .
  • Offer letter: initial base salary $300,000; annual bonus up to 40% (50% corporate, 50% individual); 60,000 RSU grant; participation in Severance & CIC Plan .
  • Severance (no CIC): lump sum equal to salary for minimum 2 weeks plus 2 weeks per year of service (max 26 weeks); earned but unpaid bonuses; one month medical premium .
  • Qureshi severance (no CIC) specific: 26 weeks salary and COBRA for six months (or lump sum equivalent), plus any earned but unpaid bonuses .
  • Change‑in‑control (double trigger): if terminated without cause within 3 months before or 12 months after a CIC, six months of salary, any earned but unpaid bonuses, and immediate vesting of all unvested equity .
  • Clawback policy: recovery of incentive compensation upon restatement, recalculation of plan measures, or misconduct; no clawback actions in 2024 .
  • Non‑compete/non‑solicit and NDA required per offer letter; employment disputes (termination-related claims) subject to binding arbitration in King County, WA .

Performance & Track Record

  • 2024 operational progress: margin restoration, strengthened capital position, record free cash flow; intrinsic value estimated up ~$879M to $2.01B; incentives reflect higher attainment in 2H 2024 .
  • Capital structure actions: led 2025 refinancing into a lower-cost $120M PNC facility to support growth and flexibility .
  • Investor Day commentary: targeted 15% adjusted operating margin at full-year; focus on pricing discipline and returning growth driver to pet count .

Compensation Committee & Say‑on‑Pay

  • Compensation Committee: Howard Rubin (Chair), Betsy McLaughlin, Richard Enthoven; independent consultant shifted from Meridian to Willis Towers Watson effective Jan 1, 2025 .
  • Peer group spans animal health and insurance companies; used for market context .
  • Say‑on‑pay 2024 approval: approximately 96.4% support .

Company Performance Context (3 fiscal years)

MetricFY 2022FY 2023FY 2024
Revenue ($)$905.2M*$1,108.6M*$1,285.7M*
EBITDA ($)$(31.5)M*$(23.8)M*$12.4M*
EBITDA Margin (%)−3.48%*−2.15%*0.97%*
Net Income ($)$(44.7)M*$(44.7)M*$(9.6)M*
Cash from Operations ($)$(8.0)M*$18.6M*$48.3M*

Values retrieved from S&P Global.
Note: Revenue and net income trends corroborate 2024 proxy disclosures on growth and loss improvement .

Investment Implications

  • Pay-for-performance alignment: MIP shifts all executives, including CFO, to AOI/LVP/IRR metrics with capped payouts (200%); 2H 2024 payout at 106% indicates improving fundamentals; performance RSU pool scaled by intrinsic value growth, which was strong in 2024 .
  • Retention risk: Material unvested equity (≥54.6K RSUs at YE 2024) and double-trigger CIC protection reduce near-term attrition risk; severance terms are standard and not excessive .
  • Selling pressure: Proxy indicates RSU vesting activity (late Form 4 in Nov 2024) but no open-market sales disclosed; monitor quarterly RSU settlements and any 10b5‑1 plans for potential supply .
  • Alignment and governance: Strong say‑on‑pay support (96.4%), robust clawback/anti-hedging and ownership guidelines; plan-level ability to reprice options/SARs with consent is a governance consideration to monitor .
  • Capital discipline: Lower-cost credit facility under CFO stewardship enhances liquidity for growth investments; watch execution on margin restoration and pet-count-driven revenue to sustain TSR improvements .